Nadroparin did not prevent late-pregnancy complications compared to medical surveillance alone in women at risk of recurrence (21% vs 18%; absolute risk difference 2.2, 95% CI -1.6 to 16.0; P=0.76).
RCT (n=135)
Open-label
parallel-group
Yes
Does nadroparin prevent the recurrence of late pregnancy complications in pregnant women with a history of placenta-mediated pregnancy complications?
Prophylactic low-molecular-weight heparin (nadroparin) does not prevent the recurrence of late-pregnancy complications in high-risk women.
Effect estimate: Absolute risk difference 2.2 (95% CI -1.6 to 16.0)
Absolute Event Rate: 21% vs 18%
p-value: p=0.76
To assess whether antithrombotic prophylaxis with low-molecular-weight heparin effectively prevents recurrence of late pregnancy complications, 135 women with previous history of preeclampsia, hemolytic anemia, elevated liver enzymes and low platelet count syndrome, intrauterine fetal death, fetal growth restriction, or placental abruption who had been referred within the 12th gestational week were randomized to medical surveillance alone (n = 68) or combined to open-label nadroparin (3800 IU daily subcutaneous injections) treatment (n = 67) in the setting of a randomized, parallel-group, superiority trial, run in Italy from April 2007 to April 2010. Primary outcome was a composite end point of late-pregnancy complications. Analysis was by intention to treat. The study was stopped for futility at the time of the first planned interim analysis. Among the 128 women eventually available for final analyses, 13 of the 63 (21%) randomized to nadroparin compared with 12 of the 65 (18%) on medical surveillance alone progressed to the primary end point. The absolute event risk difference between treatment arms (2.2; -1.6 to 16.0) was not statistically significant (P = .76). Thus, nadroparin did not prevent late-pregnancy complications in women at risk of recurrence. This finding challenges the role of antithrombotic prophylaxis with low-molecular-weight heparin in the prevention of recurrent late pregnancy complications The trial was registered at http://ricerca-clinica.agenziafarmaco.it as EudraCT 2006-004205-26.
Martinelli et al. (Tue,) conducted a rct in previous placenta-mediated pregnancy complications (n=135). nadroparin vs. medical surveillance alone was evaluated on composite end point of late-pregnancy complications (Absolute risk difference 2.2, 95% CI -1.6 to 16.0, p=0.76). Nadroparin did not prevent late-pregnancy complications compared to medical surveillance alone in women at risk of recurrence (21% vs 18%; absolute risk difference 2.2, 95% CI -1.6 to 16.0; P=0.76).